Protalix BioTherapeutics (PLX) Return on Sales (2010 - 2026)

Protalix BioTherapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Sales rose 1.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales climbed to 0.01% in Q1 2026 per PLX's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2024 and bottomed at 0.02% in Q4 2023.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.0%.
• Across the five-year window, Return on Sales decreased 2 bps in 2023 and gained 3 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then tumbled by 415 bps to 0.02% in 2023, then jumped by 131 bps to 0.01% in 2024, then sank by 166 bps to 0.0% in 2025, then jumped by 239 bps to 0.01% in 2026.
• Per Business Quant, the three latest PLX Return on Sales figures stand at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).